Erratum: Unique pharmacological profile of aripiprazole as the phasic component buster (Psychopharmacology DOI: 10.1007/s00213-006-0654-2);Unique pharmacological profile of aripiprazole as the phasic component buster

Psychopharmacology

Volumn 191, Issue 3, 2007, Pages 741-743

  Hamamura, Takashi ^a   Harada, Toshiki ^b  

^a Hamamura Clinic   (Japan)

^b Takahashi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ARTICLE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY;

EID: 33847624636     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0716-0     Document Type: Erratum

References (17)

1. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389
2. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
3. Floresco SB, West AR, Ash B, Moore H, Grace AA (2003) Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6:968-973
4. Grace AA (1987) The regulation of dopamine neuron activity as determined by in vivo and in vitro intracellular recordings. In: Chiodo LA, Freeman AS (eds) The neurophysiology of dopaminergic systems - current status and clinical perspectives. LakeShore, Detroit, pp 1-67
5. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24
6. Heien ML, Wightman RM (2006) Phasic dopamine signaling during behavior, reward, and disease states. CNS Neurol Disord Drug Targets 5:99-108
7. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771
8. Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23
9. Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161-166
10. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
11. Lodge DJ, Grace AA (2006) The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. Proc Natl Acad Sci USA 103:5167-5172
12. Mallikaarjun S, Salazar DE, Bramer SL (2004) Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44:179-187
13. Schultz W (2002) Getting formal with dopamine and reward. Neuron 36:241-263
14. Seeman P, Tallerico T (1998) Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3:123-134
15. Seeman P, Tallerico T (1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156:876-884
16. Wightman RM, Robinson DL (2002) Transient changes in mesolimbic dopamine and their association with 'reward'. J Neurochem 82:721-735
17. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248-259